Form 4: Cadrenal CEO Quang Pham Sells Shares via 10b5-1 Plan

Cadrenal Therapeutics Chairman and CEO Quang Pham sold 22,385 shares of common stock across three days in June 2026.

Summary

• Quang Pham, Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., executed a series of stock sales totaling 22,385 shares.
• The sales occurred between June 8, 2026, and June 10, 2026.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025.
• Following these transactions, Mr. Pham retains direct ownership of 150,839 shares and indirect ownership of 200,000 shares via The PVBQ Living Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and represent a routine divestment rather than a reactive move.

Positives

• The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale of shares by the CEO and Chairman may be perceived by some investors as a lack of confidence in the short-term price appreciation of the stock.

Risks

• Continued selling by major insiders could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate practice for liquidity and diversification, and is generally viewed as neutral unless the volume represents a significant portion of the insider's total holdings.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while maintaining compliance with SEC regulations.
• The volume of shares sold represents a small fraction of the total holdings of the CEO, which is consistent with typical executive diversification strategies.

Related Party Transactions

• The reporting person maintains indirect ownership of 200,000 shares through The PVBQ Living Trust, where he serves as Trustee.

Stakeholder Impact

• Shareholders should note the reduction in direct ownership by the CEO, though the impact is mitigated by the pre-planned nature of the sales.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Cadrenal Therapeutics, CVKD, Insider Trading, Form 4, Quang Pham, Rule 10b5-1